Abstracts tagged "cytokines and rheumatoid arthritis (RA)"

Abstract Number: 2425 • 2017 ACR/ARHP Annual Meeting
Decline in CD8+IFNγ+ Subset but Rise in CD8+IL17+ on Methotrexate Treatment in Rheumatoid Arthritis
Amit Sandhu¹, Varun Dhir², Shabeer Ahmad¹, Prabhdeep Kaur¹, Veena Dhawan³ and Archana Bhatnagar⁴, ¹Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India, ²Internal Medicine (Rheumatology Unit), Postgraduate Institute of Medical Education and Research, Chandigarh, India, ³Experimental Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India, ⁴Biochemistry, Panjab University, Chandigarh, India
Background/Purpose: CD8 T cells comprise 40 % of all T cells in the synovial compartment and are detectable in he preclinical stages as well. They…
Abstract Number: 2701 • 2017 ACR/ARHP Annual Meeting
TNFR2+ Regulatory T Cellssubpopulations ARE Highly Suppressive and Are Increased on Anti-TNF Treatment
Francois Santinon¹, Maxime Batignes², Benoit Salomon³, Patrice Decker², Marie-Christophe Boissier⁴, Luca Semerano⁵ and Natacha Bessis², ¹INSERM UMR 1125 University of Paris 13, Sorbonne Paris Cité, bobigny, France, ²INSERM UMR 1125 University of Paris 13, Sorbonne Paris Cité, Bobigny, France, ³Sorbonne Universités, UPMC Université Paris 06, INSERM, CNRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France, ⁴Rheumatology Department, Assistance Publique – Hôpitaux de Paris (AP-HP), Avicenne Hospital, Bobigny, France, ⁵INSERM UMR 1125 University of Paris 13, Sorbonne Paris Cité and Assistance Publique – Hôpitaux de Paris (AP-HP), Avicenne Hospital, Rheumatology Department, France, Bobigny, France
Background/Purpose: In rheumatoid arthritis (RA), regulatory T cells (Tregs) are defective in their suppressive capacities and fail to control chronic inflammation. TNF-α is involved in…
Abstract Number: 2870 • 2017 ACR/ARHP Annual Meeting
Ex Vivo Comparison of Baricitinib, Upadacitinib, Filgotinib, and Tofacitinib for Cytokine Signaling in Human Leukocyte Subpopulations
Iain B. McInnes¹, Richard Higgs², Jonathan Lee², William L. Macias², Songqing Na², Robert A. Ortmann², Guilherme Rocha², Thomas Wehrman³, Xin Zhang², Steven H. Zuckerman² and Peter C. Taylor⁴, ¹University of Glasgow, Glasgow, United Kingdom, ²Eli Lilly and Company, Indianapolis, IN, ³Primity Bio, Fremont, CA, ⁴NDORMS, University of Oxford, Oxford, United Kingdom
Background/Purpose: Baricitinib (bari), an oral selective Janus kinase (JAK) 1/2 inhibitor, has been approved in the EU for the treatment of adults with moderately to…
Abstract Number: 2619 • 2016 ACR/ARHP Annual Meeting
Sustained Suppression of Peripheral Biomarkers By Mavrilimumab but Not Golimumab in Anti-Tumor Necrosis Factor-Inadequate Responders: An Exploratory Analysis in the Phase IIb Earth Explorer 2 Clinical Trial
Xiang Guo¹, Shiliang Wang¹, Anne C. Bay-Jensen², Morten Asser Karsdal², A Godwood³, Marius Albulescu³, D Close³, Patricia C. Ryan¹, Lorin Roskos⁴ and Wendy White¹, ¹Translational Sciences, MedImmune, LLC, Gaithersburg, MD, ²Rheumatology, Nordic Bioscience, Herlev, Denmark, ³MedImmune, Cambridge, United Kingdom, ⁴MedImmune, LLC, Mountain View, CA
Background/Purpose: Treatment of rheumatoid arthritis (RA) patients by anti-tumour necrosis factors (anti-TNFs), such as golimumab, has improved patient outcomes. However, unmet therapeutic needs exist for…
Abstract Number: 1567 • 2016 ACR/ARHP Annual Meeting
A Functional Genomic Screen of Rheumatoid Arthritis Risk Genes in Primary Human T Cells Reveals DDX6 As a Negative Modulator of Cytokine Expression
Rumey Ishizawar¹, Chantel Lester², Jing Cui³, John Doench⁴, Robert Plenge⁵ and Michael Brenner⁶, ¹Division of Rheumatology, Allergy, and Immunology and Thurston Arthritis Research Center, University of North Carolina, Chapel Hill, NC, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ³Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Broad Institute of MIT and Harvard, Cambridge, MA, ⁵Genetics & Pharmacogenomics, Merck Research Laboratories, Merck & Co., Boston, MA, ⁶Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: In rheumatoid arthritis (RA), genome-wide association studies have identified over 100 risk alleles. A major challenge is identifying causal genes in RA risk loci. As…
Abstract Number: 1916 • 2016 ACR/ARHP Annual Meeting
Heightened MAIT Cell Sensitivity to MR1 Ligands Could Impact Control of Dysbiosis in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis
Diahann Jansen¹, Elizabeth Klinken¹, Hendrik Nel², Soi Cheng Law², Helen Benham^3,4,5, Lisa Cummins⁶, Matthew Brown⁷, Tony Kenna², Ligong Liu⁸, David Fairlie⁸, Jamie Rossjohn^9,10,11, Mark Morrison³, Ranjeny Thomas³, Paraic O Cuiv¹, James McCluskey¹² and Alexandra Corbett¹², ¹The University of Queensland Diamantina Institute, Translational Research Institute, Woolloongabba, Australia, ²The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Australia, ³Translational Research Institute, The University of Queensland Diamantina Institute, Woolloongabba, Australia, ⁴University of Queensland School of Medicine, Brisbane, Australia, ⁵Rheumatology, Princess Alexandra Hospital, Woolloongabba, Australia, ⁶Princess Alexandra Hospital, Woolloongabba, Australia, ⁷Queensland University of Technology, Brisbane, Australia, ⁸Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia, ⁹Infection and Immunity Program, Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Clayton, Australia, ¹⁰Institute of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom, ¹¹Australian Research Council Centre of Excellence in Advanced Molecular Imaging, Monash University, Clayton, Australia, ¹²Department of Microbiology & Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, Australia
Background/Purpose: Mucosal associated invariant T (MAIT) cells are an innate-like lymphocyte population predominant at mucosal sites, which express a semi-invariant T cell receptor restricted to…
Abstract Number: 2116 • 2016 ACR/ARHP Annual Meeting
Cytokines Inhibition Modulates Activation and Homing Receptor of Different Peripheral Memory B Cell Subsets in RA
Zafar Mahmood¹, Marc Schmalzing², Michael Gernert³, Thomas Dörner⁴ and Hans-Peter Tony³, ¹Department of Medicine II, Rheumatology/Clinical Immunology, University of Würzburg, Würzburg, Germany, ²Rheumatology/Clinical Immunology, Medical Clinic II, University Clinic Wuerzburg, Würzburg, Germany, ³Rheumatology/Immunology, Medical Clinic II, University Clinic Wuerzburg, Würzburg, Germany, ⁴Charité - Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: With the advent of B cell targeted therapies the modulation of memory B cells seems to be a prime target. Human peripheral memory B…
Abstract Number: 530 • 2015 ACR/ARHP Annual Meeting
Immunomodulation of Naïve RA Patients PBMCs with a Multi-Epitope Peptide Derived from Citrullinated Autoantigens
Smadar Gertel¹, Yehuda Shoenfeld² and Howard Amital³, ¹Sheba Medical Center, Zabludowicz Center for Autoimmune Diseases, affiliated to Sackler Faculty of Medicine, Tel-Aviv University, Ramat Gan, Israel, ²Head Dept of Medicine B, Sheba Medical Center, Ramat-Gan, Israel, ³Sheba Medical Center, Tel-Hashomer, Israel
Background/Purpose: Citrullinated peptides are major targets of disease-specific autoantibodies in rheumatoid arthritis (RA). We generated a multi-epitope citrullinated peptide (Cit-ME), derived from major prevalent citrullinated…
Abstract Number: 3152 • 2015 ACR/ARHP Annual Meeting
The IL-21 Signaling Pathway Is Enhanced in RA B Cells and Has the Potential to Alter Development and Cytokine Production in RA B Cells
Jane H. Buckner¹ and Elizabeth Samuelson², ¹Benaroya Research Institute at Virginia Mason, Seattle, WA, ²Translational Research, Benaroya Research Institute at Virginia Mason, Seattle, WA
Background/Purpose: B cells have been implicated in the development of rheumatoid arthritis (RA) based on their production of autoantibodies and cytokines as well as the…
Abstract Number: 2821 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety/Tolerability of Mavrilimumab, a Human GM-CSFRÃ¡ Monoclonal Antibody in Patients with Rheumatoid Arthritis
Gerd Burmester¹, Iain B. McInnes², Joel M. Kremer³, Pedro Miranda⁴, Mariusz Korkosz⁵, Jiri Vencovsky⁶, Andrea Rubbert-Roth⁷, Eduardo Mysler⁸, Sara Sandbach⁹, Matthew A. Sleeman¹⁰, Alex Godwood¹¹, David Close¹² and Michael Weinblatt¹³, ¹Department of Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Berlin, Germany, ²University of Glasgow, Glasgow, United Kingdom, ³Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY, ⁴Centro de Estudios Reumatologicos, Santiago, Chile, ⁵Inernal Medicine and Gerontology, Malopolskie Centrum Medyczne, Krakow, Poland, ⁶Rheumatology, Charles University Institute of Rheumatology, Praha, Czech Republic, ⁷Med Clinic I, University of Cologne, Koln, Germany, ⁸Rheumatology, OMI, Buenos Aires, Argentina, ⁹Clinical biologics, MedImmune Ltd, Cambridge, United Kingdom, ¹⁰Respiratory, Inflammation and Autoimmunity, MedImmune Ltd, Cambridge, United Kingdom, ¹¹Clinical Biostatics and Data Management, MedImmune Ltd, Cambridge, United Kingdom, ¹²Clinical Development, MedImmune Ltd, Cambridge, United Kingdom, ¹³Rheumatology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose Granulocyte-macrophage colony-stimulating factor (GM-CSF) is implicated in RA pathogenesis via myeloid and granulocyte cell lineage activation. In a prior Phase 2a study (NCT01050998), mavrilimumab,…
Abstract Number: 2800 • 2014 ACR/ARHP Annual Meeting
Tofacitinib Regulates Synovial Angiogenesis in Psoriatic Arthritis through Induction of Negative Feedback Inhibitors
Wei Gao, Jennifer McCormick, Carl Orr, Mary Connolly, Ursula Fearon and Douglas J. Veale, Dublin Academic Medical Centre, Translational Rheumatology Research Group, Dublin, Ireland
Background/Purpose: Psoriatic Arthritis (PsA) is a common, chronic immune-mediated inflammatory disease, characterised by synovitis, progressive destruction of articular cartilage/bone, and is associated with psoriasis. Janus…
Abstract Number: 1465 • 2014 ACR/ARHP Annual Meeting
Follicular Helper T Cells Control Autoimmunity through IL-21/IL-21 Receptor Interaction in RA Patients
Shikha Singla¹, Minzi Chen², Jerry Pounds Jr.², Omar Khan², Jerald M. Zakem², Kismet Collins², Tamika Webb-Detiege², William E. Davis², Robert Quinet² and Xin Zhang³, ¹Rheumatology, Ochner Medical Center, New Orleans, LA, ²Rheumatology, Ochsner Medical Center, New Orleans, LA, ³Institute of Translational Research, Ochsner Medical Center, New Orleans, LA
Background/Purpose Rheumatoid Arthritis (RA) is an autoimmune disease characterized by chronic inflammation of the synovium, causing progressive joint destruction and reduction in quality of life…
Abstract Number: 366 • 2014 ACR/ARHP Annual Meeting
Soluble 4-1BB Is a Marker of Joint Involvement and Disease Activity in Rheumatoid Arthritis
Morten Aagaard Nielsen¹, Thomas Andersen², Kristian Stengaard-Pedersen³, Kim Hoerslev-Petersen⁴, Merete Lund Hetland⁵, Peter Junker⁶, Mikkel Ostergaard⁷, Malene Hvid¹ and Bent Deleuran⁸, ¹Department of Biomedicine, Aarhus University, Aarhus, Denmark, ²Dept. of Biomedicine, Aarhus University, Aarhus, Denmark, ³Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁴Rheumatology, Research Unit at King Christian X Hospital for Rheumatic Diseases, Graasten, Denmark, ⁵DANBIO, Center for Rheumatology and Spine Diseases, Glostrup University Hospital, Glostrup, Denmark, Glostrup, Denmark, ⁶University of Southern Denmark, Odense, Denmark, ⁷Copenhagen University Hospital at Glostrup, Copenhagen, Denmark, ⁸Dept. of Rheumatology, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose 4-1BB is induced on T cells after antigen encounter and promotes clonal expansion and accumulation of high numbers of antigen-specific effector-type T cells primarily…
Abstract Number: 1727 • 2013 ACR/ARHP Annual Meeting
Novel Selective Inhibitors Of Nuclear Export Attenuate Inflammation and Prevent Bone Mineral Density Loss In Multiple Preclinical Models Of Rheumatoid Arthritis
Mwanasha Hamuza¹, Yosef Landesman¹, Boris Klebanov¹, Michael Kauffman¹, Sharon Shacham¹, Judith Endres², David A. Fox³ and Dilara McCauley¹, ¹Karyopharm Therapeutics Inc., Natick, MA, ²Rheumatology/Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI, ³Rheumatology/Int Medicine, University of Michigan Medical Center, Ann Arbor, MI
Background/Purpose: Exportin 1 (XPO1; also called chromosome region maintenance 1, CRM1) is a key protein that controls the export of ~220 cargo proteins and several…
Abstract Number: 1459 • 2013 ACR/ARHP Annual Meeting
Multiple Cytokine Profiling Predicts The Effectiveness Of Switching Biologics In Rheumatoid Arthritis
Kensuke Koyama¹, Katsunori Ikari¹, Atsuo Taniguchi², Shigeki Momohara² and Hisashi Yamanaka¹, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: There is some rheumatoid arthritis (RA) patients with poor responses to certain biologics which requires switching to another biologics. However, there is no solid…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.